Originally published as JCO Early Release 10.1200/JCO.2007.13.2415 on December 17 2007

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sureda, A. Articles by Schmitz, N. Search for Related Content PubMed PubMed Citation Articles by Sureda, A. Articles by Schmitz, N. Related Articles Related Correspondence Social Bookmarking                            What's this?

Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

Anna Sureda, Stephen Robinson, Carmen Canals, Angelo M. Carella, Marc A. Boogaerts, Dolores Caballero, Ann E. Hunter, Lothar Kanz, Shimon Slavin, Jan J. Cornelissen, Martin Gramatzki, Dietger Niederwieser, Nigel H. Russell, Norbert Schmitz

From the Clinical Hematology Division, Hospital de la Santa Creu i Sant Pau, Barcelona; Departmento de Hematologia, Hospital Clinico Universitario, Salamanca, Spain; Department of Paediatric Oncology/Bone Marrow Transplantation, Bristol Royal Hospital for Children, Bristol; Department of Haematology, Leicester Royal Infirmary, Leicester; Nottingham City Hospital, Nottingham, United Kingdom; Azienda Ospedaliera Universitaria San Martino, Genoa, Italy; Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium; Medizinische Klinik, Universität Tübingen; Division of Stem Cell Transplantation and Immunotherapy, 2nd Medical Department, University Hospital Schleswig-Holstein Keil Campus, Kiel; Division of Hematology and Oncology, University Hospital Leipzig, Leipzig; Department of Haematology, Asklepios Klinik St Georg, Hamburg, Germany; Blood and Bone Marrow Tansplantation, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; and Erasmus MC-Daniel den Hoed Cancer Center, Rottendam, the Netherlands

Corresponding author: Anna Sureda, MD, Clinical Hematology Division, Hospital de la Santa Creu i Sant Pau, Antoni Maria i Claret, 167, 08025 Barcelona, Spain; e-mail: asureda{at}santpau.es

Purpose To compare the clinical outcome in terms of nonrelapse mortality (NRM), relapse rate (RR), overall survival (OS), and progression-free survival (PFS) in patients with relapsed Hodgkin's lymphoma (HL) treated with reduced-intensity conditioning (RIC) or myeloablative conditioning followed by allogeneic stem-cell transplantation (alloSCT).

Patients and Methods A total of 168 patients with HL undergoing a first alloSCT (RIC, n = 89; myeloablative conditioning, n = 79) between January 1997 and December 2001 and registered in the European Group for Blood and Marrow Transplantation database were analyzed.

Results NRM was significantly decreased in the RIC group (hazard ratio [HR], 2.85; 95% CI, 1.62 to 5.02; P < .001). OS was better in the RIC group (HR, 2.05; 95% CI, 1.27 to 3.29; P = .04) and there was a trend for better PFS in the RIC group (HR, 1.53; 95% CI, 0.97 to 2.40; P = .07). RR was higher in the RIC group in univariate but not in multivariate analysis. The development of chronic graft-versus-host disease (GVHD) significantly decreased the incidence of relapse, which translated into a trend for a better PFS.

Conclusion The lower incidence of NRM in the RIC group is encouraging, particularly because these patients experienced adverse pretransplantation characteristics more frequently. This analysis also indicates the existence of a graft-versus-HL effect correlated to the development of GVHD. Additional efforts to reduce the high RR seen in both groups of patients will be necessary to improve the modest PFS (31% v 27%) and OS (59% v 36%) for patients prepared with RIC or myeloablative conditioning.

published online ahead of print at www.jco.org on December 17, 2007.

Presented in part at the 45th Annual Meeting of the American Society of Hematology, December 6-9, 2003, San Diego, CA.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Correspondence

• Superiority of Reduced-Intensity Conditioning for Hodgkin's Lymphoma
  Koen W. van Besien
  JCO 2008 26: 4045-4046 [Full Text]

This article has been cited by other articles:

				N. Schmitz, A. Sureda, G. Dini, A. Claviez, and on behalf of the Lymphoma and Pediatric Diseases W Allogeneic transplantation for children and adolescents with Hodgkin lymphoma Blood, November 12, 2009; 114(20): 4605 - 4606. [Full Text] [PDF]

				A. Claviez, C. Canals, D. Dierickx, J. Stein, I. Badell, A. Pession, S. Mackinnon, S. Slavin, J.-H. Dalle, M. J. Chacon, et al. Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation Blood, September 3, 2009; 114(10): 2060 - 2067. [Abstract] [Full Text] [PDF]

				C. Kyriakou, C. Canals, J. Finke, G. Kobbe, J.-L. Harousseau, H.-J. Kolb, N. Novitzky, A. H. Goldstone, A. Sureda, and N. Schmitz Allogeneic Stem Cell Transplantation Is Able to Induce Long-Term Remissions in Angioimmunoblastic T-Cell Lymphoma: A Retrospective Study From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation J. Clin. Oncol., August 20, 2009; 27(24): 3951 - 3958. [Abstract] [Full Text] [PDF]

				A. Engert, D. A. Eichenauer, M. Dreyling, and On behalf of the ESMO Guidelines Working Group Hodgkin's lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv108 - iv109. [Full Text] [PDF]

				E. Brusamolino, A. Bacigalupo, G. Barosi, G. Biti, P. G. Gobbi, A. Levis, M. Marchetti, A. Santoro, P. L. Zinzani, and S. Tura Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up Haematologica, April 1, 2009; 94(4): 550 - 565. [Abstract] [Full Text] [PDF]

				J. H. Mendler and J. W. Friedberg Salvage Therapy in Hodgkin's Lymphoma Oncologist, April 1, 2009; 14(4): 425 - 432. [Abstract] [Full Text] [PDF]

				S. P. Robinson, A. Sureda, C. Canals, N. Russell, D. Caballero, A. Bacigalupo, A. Iriondo, G. Cook, A. Pettitt, G. Socie, et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome Haematologica, February 1, 2009; 94(2): 230 - 238. [Abstract] [Full Text] [PDF]

				P. Armand, S. Gannamaneni, H. T. Kim, C. S. Cutler, V. T. Ho, J. Koreth, E. P. Alyea, A. S. LaCasce, E. D. Jacobsen, D. C. Fisher, et al. Improved Survival in Lymphoma Patients Receiving Sirolimus for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation With Reduced-Intensity Conditioning J. Clin. Oncol., December 10, 2008; 26(35): 5767 - 5774. [Abstract] [Full Text] [PDF]

				B. G. M. Durie Crossover confusion: MPT still best Blood, October 15, 2008; 112(8): 2998 - 2999. [Full Text] [PDF]

				A. Sureda, S. Robinson, C. Canals, and N. Schmitz In Reply J. Clin. Oncol., August 20, 2008; 26(24): 4046 - 4047. [Full Text] [PDF]

				K. W. van Besien Superiority of Reduced-Intensity Conditioning for Hodgkin's Lymphoma J. Clin. Oncol., August 20, 2008; 26(24): 4045 - 4046. [Full Text] [PDF]

				M. Crump Management of Hodgkin Lymphoma in Relapse after Autologous Stem Cell Transplant Hematology, January 1, 2008; 2008(1): 326 - 333. [Abstract] [Full Text] [PDF]